Not Signed In - Phase III ACTEMRA(TM) (tocilizumab) Study Results Demonstrate Significant Improvement In Signs And Symptoms Of Patients With Rheumatoid Arthritis
Thu, 25 Jan 2007 08:00 AM EST
... Roche today announced that results from the OPTION (TOcilizumab Pivotal Trial in Methotrexate Inadequate respONders) trial, the first international Phase III study of ACTEMRA(TM) outside of Japan, successfully met its primary endpoint in patients with moderate to severe rheumatoid arthritis (RA) who had an inadequate response to methotrexate, a current standard of care. [click link for full article] ...
Related Topics
- Rheumatoid Arthritis
- Arthritis
- Juvenile Rheumatoid Arthritis
- Rheumatoid Factor
- Rituximab
- The signs and symptoms related to the central nervous system may be irreversible if treatment is not begun within 6 months of when these symptoms begin.
- Arthritis, Rheumatoid
- Antithrombin III
- Signs And Symptoms, Respiratory
- Osteoarthritis
- Adalimumab
- Pregnancy
- Septic Arthritis
- Infliximab
- Reactive Arthritis
- Preeclampsia
- Ovarian Cancer
- Permanent and significant neurologic problems
- Familial Dysautonomia
- Cocaine Abuse
email this page
print this page
bookmark this page
feedback on this page
